KR20080008378A - 크로만 및 크로멘 유도체 및 이의 용도 - Google Patents

크로만 및 크로멘 유도체 및 이의 용도 Download PDF

Info

Publication number
KR20080008378A
KR20080008378A KR1020077027247A KR20077027247A KR20080008378A KR 20080008378 A KR20080008378 A KR 20080008378A KR 1020077027247 A KR1020077027247 A KR 1020077027247A KR 20077027247 A KR20077027247 A KR 20077027247A KR 20080008378 A KR20080008378 A KR 20080008378A
Authority
KR
South Korea
Prior art keywords
formula
methyl
compound
mmol
chromen
Prior art date
Application number
KR1020077027247A
Other languages
English (en)
Korean (ko)
Inventor
개빈 데이비드 헤퍼난
개리 폴 스택
조나단 레어드 그로스
다후이 저우
홍 가오
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20080008378A publication Critical patent/KR20080008378A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
KR1020077027247A 2005-04-22 2006-04-21 크로만 및 크로멘 유도체 및 이의 용도 KR20080008378A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67382005P 2005-04-22 2005-04-22
US60/673,820 2005-04-22

Publications (1)

Publication Number Publication Date
KR20080008378A true KR20080008378A (ko) 2008-01-23

Family

ID=36888961

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077027247A KR20080008378A (ko) 2005-04-22 2006-04-21 크로만 및 크로멘 유도체 및 이의 용도

Country Status (19)

Country Link
US (2) US7365095B2 (US20060258714A1-20061116-C00008.png)
EP (1) EP1874756A1 (US20060258714A1-20061116-C00008.png)
JP (1) JP2008538576A (US20060258714A1-20061116-C00008.png)
KR (1) KR20080008378A (US20060258714A1-20061116-C00008.png)
CN (1) CN101203505A (US20060258714A1-20061116-C00008.png)
AR (1) AR056320A1 (US20060258714A1-20061116-C00008.png)
AU (1) AU2006239937A1 (US20060258714A1-20061116-C00008.png)
BR (1) BRPI0610027A2 (US20060258714A1-20061116-C00008.png)
CA (1) CA2605587A1 (US20060258714A1-20061116-C00008.png)
CO (1) CO6321153A2 (US20060258714A1-20061116-C00008.png)
GT (1) GT200600166A (US20060258714A1-20061116-C00008.png)
IL (1) IL186837A0 (US20060258714A1-20061116-C00008.png)
MX (1) MX2007013163A (US20060258714A1-20061116-C00008.png)
NO (1) NO20075641L (US20060258714A1-20061116-C00008.png)
PE (1) PE20061297A1 (US20060258714A1-20061116-C00008.png)
RU (1) RU2007139541A (US20060258714A1-20061116-C00008.png)
TW (1) TW200716595A (US20060258714A1-20061116-C00008.png)
WO (1) WO2006116165A1 (US20060258714A1-20061116-C00008.png)
ZA (1) ZA200709052B (US20060258714A1-20061116-C00008.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204064A1 (ko) * 2013-06-21 2014-12-24 제주대학교 산학협력단 신규 플라보노이드 및 그 용도
EP3923919A4 (en) * 2019-02-17 2022-12-07 Neurawell Therapeutics COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION AND OTHER DISORDERS

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用
MX2007013151A (es) * 2005-04-22 2008-01-16 Wyeth Corp Derivados de benzodioxano y benzodioxolano y usos de los mismos.
AU2006239910A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060258713A1 (en) * 2005-04-22 2006-11-16 Wyeth Treatment of pain
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
GT200600164A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
MX2007013163A (es) * 2005-04-22 2008-01-21 Wyeth Corp Derivados de cromano y cromeno y usos de los mismos.
WO2006116221A2 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function
WO2007112065A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
CL2007003043A1 (es) * 2006-10-24 2008-05-30 Wyeth Corp Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros.
WO2008052088A1 (en) * 2006-10-25 2008-05-02 Wyeth Chromane derivatives, synthesis thereof, and intermediates thereto
CA2988753A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US8914112B2 (en) 2008-01-23 2014-12-16 Boston Scienctific Neuromodulation Corporation Methods and systems of treating pancreatitis pain caused by sphincter of Oddi dysfunction
US8676322B2 (en) 2008-01-30 2014-03-18 Boston Scientific Neuromodulation Corporation Methods and systems of treating pancreatitis pain
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
EP2296686B2 (en) 2008-05-21 2017-11-01 Ferring B.V. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
CN101921252B (zh) * 2010-07-02 2012-05-09 中国科学院上海有机化学研究所 1-氧杂苯并杂环类化合物、合成方法和用途
WO2012087289A1 (en) 2010-12-21 2012-06-28 Colgate-Palmolive Company Halogenated biphenols as antibacterial agents
CN109970533B (zh) * 2012-12-18 2022-06-14 帝斯曼知识产权资产管理有限公司 由(r)-6,10,14-三甲基十五碳-5-烯-2-酮制备的(6r,10r)-6,10,14-三甲基十五烷-2-酮
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
SG11201706515QA (en) 2015-02-11 2017-09-28 Sunovion Pharmaceuticals Inc 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EP3494119A4 (en) 2016-07-29 2020-03-25 Sunovion Pharmaceuticals Inc. CONNECTIONS AND COMPOSITIONS AND USES THEREOF
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
EP3661929B1 (en) 2017-08-02 2021-07-14 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CA3130849A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262078A (en) 1968-05-24 1972-02-02 Fisons Pharmaceuticals Ltd Preparation of phenoxy fumaric acid compounds and chromone-2-carboxylic acid compounds therefrom
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5089637A (en) 1990-03-21 1992-02-18 Pfizer Inc. Process and intermediates for 2r-benzyl-chroman-6-carbaldehyde
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
NZ271995A (en) 1993-08-19 1996-11-26 Janssen Pharmaceutica Nv 2-(aminoalkyl)dihydrobenzopyran derivatives; medicaments; and intermediate compounds
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
DE4430089A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verfahren zur enzymatischen Herstellung von enantiomerenreinen Chroman-2-carbonsäuren und deren Derivaten
EP0707007B1 (en) 1994-10-14 2001-12-12 MERCK PATENT GmbH (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent
US5658796A (en) 1995-06-07 1997-08-19 Seprachem, Inc. Optical resolution of alkyl chroman-2-carboxylates
CA2276278C (en) 1997-02-27 2009-04-07 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
FR2763335B1 (fr) 1997-05-16 2000-11-24 Adir Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US20060258176A1 (en) * 1998-02-05 2006-11-16 Asm Japan K.K. Method for forming insulation film
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
FR2791675B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
DE10044091A1 (de) 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
UA75898C2 (en) 2000-11-14 2006-06-15 Merck Patent Gmbh Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors
DE10120619A1 (de) 2001-04-26 2002-10-31 Merck Patent Gmbh 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
CN1536998A (zh) 2001-08-01 2004-10-13 Ĭ��ר�����޹�˾ 用于治疗眼病的整联蛋白抑制剂
EP1432696A1 (en) * 2001-10-04 2004-06-30 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
MXPA04003086A (es) 2001-10-05 2004-09-06 Wyeth Corp Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos.
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
WO2003031428A1 (en) 2001-10-05 2003-04-17 Wyeth Stereospecific process for the synthesis of 2-yl chroman derivatives
US20050014818A1 (en) 2001-11-09 2005-01-20 Masaru Mitsuda Process for producing optically active chroman derivative and intermediate
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
AU2003291012A1 (en) 2002-11-15 2004-06-15 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
DE10348257A1 (de) 2003-10-16 2005-05-25 Merck Patent Gmbh Verfahren zur Herstellung von enantiomereneinen in 2-Position substituierten Chromanderivaten
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
DE102004011265A1 (de) 2004-03-09 2005-09-29 Lutz F. Prof. Dr. Tietze Synthese von Vitamin E
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
CA2588909A1 (en) 2004-11-24 2006-06-22 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
MX2007013163A (es) * 2005-04-22 2008-01-21 Wyeth Corp Derivados de cromano y cromeno y usos de los mismos.
WO2006116149A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用
MX2007013151A (es) * 2005-04-22 2008-01-16 Wyeth Corp Derivados de benzodioxano y benzodioxolano y usos de los mismos.
WO2006116221A2 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
AU2006239910A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
US20060258713A1 (en) * 2005-04-22 2006-11-16 Wyeth Treatment of pain
AU2006239917A1 (en) * 2005-04-22 2006-11-02 Wyeth (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
EP1874292A2 (en) * 2005-04-24 2008-01-09 Wyeth Methods for modulating bladder function

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204064A1 (ko) * 2013-06-21 2014-12-24 제주대학교 산학협력단 신규 플라보노이드 및 그 용도
EP3923919A4 (en) * 2019-02-17 2022-12-07 Neurawell Therapeutics COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION AND OTHER DISORDERS

Also Published As

Publication number Publication date
NO20075641L (no) 2007-11-20
EP1874756A1 (en) 2008-01-09
RU2007139541A (ru) 2009-05-27
AU2006239937A1 (en) 2006-11-02
TW200716595A (en) 2007-05-01
US20080182891A1 (en) 2008-07-31
WO2006116165A1 (en) 2006-11-02
GT200600166A (es) 2007-03-14
US7365095B2 (en) 2008-04-29
CN101203505A (zh) 2008-06-18
JP2008538576A (ja) 2008-10-30
BRPI0610027A2 (pt) 2010-05-18
US20060258714A1 (en) 2006-11-16
CO6321153A2 (es) 2011-09-20
CA2605587A1 (en) 2006-11-02
ZA200709052B (en) 2009-08-26
MX2007013163A (es) 2008-01-21
AR056320A1 (es) 2007-10-03
IL186837A0 (en) 2008-02-09
PE20061297A1 (es) 2006-12-24

Similar Documents

Publication Publication Date Title
KR20080008378A (ko) 크로만 및 크로멘 유도체 및 이의 용도
KR20080009295A (ko) 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
US7368477B2 (en) Benzofuranyl alkanamine derivatives and uses thereof
US20060258739A1 (en) Dihydrobenzofuran derivatives and uses therof
CA2604916A1 (en) Dihydrobenzofuran derivatives and uses thereof
JP2007509174A (ja) 5ht2cアゴニストとしてのジヒドロベンゾフラニルアルカンアミン誘導体
WO2008052086A1 (en) Benzodioxane derivatives and uses thereof
EP2470520A1 (en) Chromone derivatives, a process for their preparation and their therapeutic applications
US20100035871A1 (en) Benzoxazine derivatives and uses thereof
US20100160411A1 (en) Benzoxathiine and benzoxathiole derivatives and uses thereof
WO2008052087A1 (en) Chromane derivatives and uses thereof

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid